Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2005-09-27
2005-09-27
Nguyen, Dave Trong (Department: 1632)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C435S320100, C435S069100, C435S325000, C435S091400
Reexamination Certificate
active
06949242
ABSTRACT:
The invention relates to a recombinant vector for the cloning and/or expression and/or transfer of an exogenous nucleotide sequence characterized in that it consists of any sequence contained in the ClaI-PvuII fragment comprising nucleotides 7702 to 1527 (SEQ ID NO: 11) of the sequence given in FIGS. 1A-1D and comprising the LTR sequence included between nucleotides 7842 and 144, the PBS site starting at nucleotides 145, the packaging sequence included in the sequences of 250 nucleotides following the end of the LTR sequence, the said sequence being capable of controlling the cloning and/or expression and/or transfer at the exogenous sequence whatever its transcriptional orientation with respect to the transcriptional orientation of the virus. It relates to the use of this vector for the transfer and/or cloning and/or expression of genes, in particular in the context of gene therapy.
REFERENCES:
patent: 4650764 (1987-03-01), Temin et al.
patent: 5124263 (1992-06-01), Temin et al.
patent: 611 822 (1994-02-01), None
patent: 632 129 (1994-05-01), None
patent: 2707091 (1993-05-01), None
patent: WO 89/11539 (1989-11-01), None
patent: WO 90/02797 (1990-03-01), None
patent: WO 90/06757 (1990-06-01), None
patent: WO 91/12329 (1991-08-01), None
patent: WO 92/05266 (1992-04-01), None
patent: WO 94/05780 (1994-03-01), None
Kabat, D., “Molecular Biology of Friend Viral Erythroleukemia”,Current Topics in Microbiology and Immunology, 148:1-42 (1989).
Watson et al. (1987) in : Molecular Biology of the Gene, Benjamin/Cummings Publ. Co., Menlo Park, CA, p. 313.
O. Cohen-Haguenauer, et al.; “Transduction of human CD34+ haemopoietic progenitors of various origin using an original retrovirus vector derived from Fr-MuLV and Clinically relevant procedures”;Hematology Cell Therapy 1996; pp. 205-206 (copy enclosed).
Joyner et al.,Prog. Cancer Res. Ther., 30:89-96 (1984).
Feldman et al.,J. Virology, 63(12):5469-5474 (1989).
Holland et al.,PNAS USA, 84: 8662-8666 (1987).
Velu et al.,Human Gene Transfer, 219: 273-274 (1991).
Bestwick et al., “Overcoming Interference to Retroviral Superinfection Results in Amplified Expression and Transmission of Cloned Genes”,Proc. Natl. Acad. Sci. USA, 85:5404-5408 (Aug. 1988).
Danos et al., “Safe and Efficient Generation of Recombinant Retroviruses with Amphotropic and Ecotropic Host Ranges”,Proc. Natl. Acad. Sci. USA, 85: 6460-6464 (Sep. 1988).
Mclachlin et al., “Retroviral-Mediated Gene Transfer”,Progress in Nucleic Acid Res. and Molecular Biology, 38: 91-135, (1990).
Mulligan RC, “The Basic Science of Gene Therapy”,Science, 260:926-931 (May 14, 1993).
Perryman et al., “Complete Nucleotide Sequence of Friend Murine Leukemia Virus, Strain FB29”,Nucleic Acids Res., 19:6950 (Nov. 1991).
Perryman et al., “Retroviral Expression Vector pSFF DNA, Complete Sequence”,Nucleic Acids Res, cited in GenBank Database, Bethesda, US, GenBank ACC. No. (GBN):Z22761 (May 19, 1993).
Sitbon et al., “Hemolytic Anemia and Erythroleukemia, Two Distinct Pathogenic Effects of Friend MuLV: Mapping of the Effects to Different Regions of the Viral Genome”,Cell, 47:851-859 (Dec. 1986).
Temin H.M., “Safety Considerations in Somatic Gene Therapy of Human Disease with Retrovirus Vectors”,Hum. Gene Ther., 1:111-123, (1990).
Sitbon et al., “Sequences in the U5-gag-pol Region Influence Early and Late Pathogenic Effects of Friend and Moloney Murine Leukemia Viruses”,U. Virol., 64:2135-2140 (May 1990).
Yu et al., “Open Reading Frame vpr of Simian Immunodeficiency Virus encodes a Virion-Associated Protein”,J. Virol.64:5688-5693 (Nov. 1990).
Yu et al., “Self -Inactivating Retroviral Vectors Designed for Transfer of Whole Genes Into Mammalian Cell”,Proc. Natl. Acad. Sci., 83:3194-3198 (May 1986).
Fields, et al.; “Transformation by Molecular Mimicry and Insertional Mutagenesis: Friend Leukemia Virus”;Virology; pp. 323-324 (1996). (copy enclosed).
Ruan K.S., et al.; “Approach to a retrovirus vaccine: Immunization of mice against Friend virus disease with a replication-defective”;Proc. Natl. Acad. Sci. US; 89:24 (Dec. 15, 1992). Accession No. 93101695 Medline abstract of Proc. Natl. Acad. Sci. 89:12202-6. (copy enclosed).
Jolly, D., “Viral vector systems for gene therapy”,Cancer Gene Therapy, 1(1):51-64 (1994).
Berger et al., Accession No 86016806 Medline abstract of Proc. Natl. Acad. Sci. 82: 6913 (Oct. 1985).
Evans et al., Accession No. 80052056 Medline abstract of J. Virology 31: 133 (Jul. 1979).
Corrine Ronfort et al., “Defective Retroviral Endogenous RNA is Efficiently Transmitted by Infectious Particles Produced on an Avian Retroviral Vector Packaging Cell Line”, Virology 207:271-275 (Feb. 1995).
Corrine Ronfort et al., “Structure and Expression of Endogenous Retroviral Sequences in the Permanent LMH Chicken Cell Line”, Poultry Science, 74, 127-135 (1995).
Idali Martinez et al., “Improved Retroviral Packaging Lines Derived from Spleen Necrosis Virus”, Virology 208: 234-241 (1995).
Francois Loic Cosset et al., “A New Avian Leukosis Virus-Based Packaging Cell Line that uses Two Separate Transcomplementing Helper Genomes”, Journal of virology, 64(3):10704078(Mar. 1990).
Francois Loic Cosset et al., “High-Titer Packaging Cells Producing Recombinant Retroviruses Resistant to Human Serum”, Journal of virology, 69(12):7430-74366(Dec. 1995).
M.E. Hotalin et al., “Amplified and tissue-directed expression of retroviral vectors using ping-pong techniques”, J. Mol. Med. 73:113-120(1995).
Rolf M. Flugel et al., “Nucleotide sequence analysis of the env gene and its flanking regions of te human spumaretrovirus reveals two novel genes”, The EMBO Journal 6(7):2077-2084(1987).
Bosselman et al., “Replication-Defective Chimeric Helper Proviruses and Factors Affecting Generation of Competent Virus: Expression of Moloney Murine Leukemia Virus Structural Genes via the Metallothionein Promotor ”, Mol. Cell. Biol., vol. 7, No. 5, pp. 1797-1806 (May 1987).
Fields, B., et al., “Cell Transformation by Viruses”,Virology, 3rd Edition, p. 323 (1996).
Verman, Gene Therapy: Beyond 2000, Jun. 2000, Molecular Therapy, vol. 1, No. 6 p. 493.
Dang et al., Gene Therapy and Translational Cancer Research, Feb. 1999. Feb. 1999, Clinical Cancer Research, vol. 5 pp. 471-474.
Orkin et al., Report and Recommendations of the Panel to Assess the NIH Investment in research on gene therapy, Dec. 1995, distributed by the National Institutes of Health, Bethesda, MD or www.nih.gov.
Verma et al., Gene therapy-promises, problems and prospects, Sep. 1997, Nature, vol. 389 pp. 239-242.
Merchant & Gould P.C.
Nguyen Dave Trong
LandOfFree
Retroviral vector for the transfer and expression of genes... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Retroviral vector for the transfer and expression of genes..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Retroviral vector for the transfer and expression of genes... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3405759